It wasn't so long ago when Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) stocks were flying high thanks to their hotly popular weight loss drugs (Wegovy/Ozempic for Novo Nordisk and ...

The study did not meet its primary endpoint of efficacy against acute gastroenteritis events due to GI.1 or GII.4 norovirus genotypes. No clinical benefit was observed across secondary endpoints.

Makers of weight-loss drugs, the hottest segment of the pharmaceutical market just now, weren't looking so hot on the stock exchange Tuesday. A pronouncement from President Trump about the category ...

That rival is ambitious clinical-stage biotech Viking Therapeutics. The company published its second-quarter results and business update after market close on Wednesday, and the obesity drug ...